TapewireFind a company

person · Reporting owner

Strong Stewart W

Disclosed activity across 1 company

Tapewire entity
88715
SEC CIK
0001420910

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HAEMONETICS CORPHAE · Entity 3953President, Global HospitalJuly 26, 2024July 29, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HAEMONETICS CORP

Report date July 26, 2024 · Filed July 29, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect18,196 Reported balance After 2024-07-26 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2024-07-26 · Sale · Disposed 4,312 · Balance 18,196

F1: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2: This number includes unvested restricted stock units previously reported.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2: This number includes unvested restricted stock units previously reported.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 26, 2024 Filed Jul 29, 2024 21:03 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 4,312 $91.15 $393,038.80
Disclosure

SEC source: 0001127602-24-021110 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
July 25, 2024 Filed Jul 26, 2024 20:34 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 2,798 $90.58 $253,442.84
Disclosure

SEC source: 0001127602-24-021041 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,508

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
July 24, 2024 Filed Jul 26, 2024 20:34 UTC HAEMONETICS CORP HAE · Entity 3953 GrantCommon Stock 7,110 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-021041 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,306

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on July 13, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from July 13, 2021 to July 12, 2024, as certified by the Compensation Committee of the Board of Directors on Jul 24, 2024.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
May 29, 2024 Filed May 29, 2024 21:27 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 8,857 $87.53 $775,253.21
Disclosure

SEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
May 28, 2024 Filed May 29, 2024 21:27 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 4,399 $95.73 $421,116.27
Disclosure

SEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,053

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
May 28, 2024 Filed May 29, 2024 21:27 UTC HAEMONETICS CORP HAE · Entity 3953 GrantCommon Stock 13,256 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,452

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
May 20, 2024 Filed May 21, 2024 22:01 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 2,241 $0.00 Strike: $56.57 $0.00
Disclosure

SEC source: 0001127602-24-016175 · form4.xml · derivative · entry 7

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,242

Underlying: Common Stock · 2,241 shares

Expires 2028-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F8 · derivative.exercise_date: Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 20, 2024 Filed May 21, 2024 22:01 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 686 $95.11 $65,245.46
Disclosure

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 5

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 20, 2024 Filed May 21, 2024 22:01 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 1,555 $95.08 $147,849.40
Disclosure

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 4

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,882

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F6 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 20, 2024 Filed May 21, 2024 22:01 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionCommon Stock 2,241 $56.57 $126,773.37
Disclosure

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 17, 2024 Filed May 21, 2024 22:01 UTC HAEMONETICS CORP HAE · Entity 3953 GrantNon-qualified Stock Option (Right to Buy) · Derivative 6,313 $0.00 Strike: $95.73 $0.00
Disclosure

SEC source: 0001127602-24-016175 · form4.xml · derivative · entry 6

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,313

Underlying: Common Stock · 6,313 shares

Expires 2031-05-17

F7 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 17, 2024 Filed May 21, 2024 22:01 UTC HAEMONETICS CORP HAE · Entity 3953 GrantCommon Stock 2,872 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 17, 2024 Filed May 21, 2024 22:01 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 284 $95.73 $27,187.32
Disclosure

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,324

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 16, 2024 Filed May 17, 2024 21:11 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 2,410 $0.00 Strike: $57.60 $0.00
Disclosure

SEC source: 0001127602-24-015888 · form4.xml · derivative · entry 6

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,821

Underlying: Common Stock · 2,410 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 16, 2024 Filed May 17, 2024 21:11 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 733 $96.04 $70,397.32
Disclosure

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 5

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,608

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
May 16, 2024 Filed May 17, 2024 21:11 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 1,677 $96.14 $161,226.78
Disclosure

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 4

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,341

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F4 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
May 16, 2024 Filed May 17, 2024 21:11 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionCommon Stock 2,410 $57.60 $138,816.00
Disclosure

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
May 16, 2024 Filed May 17, 2024 21:11 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 252 $94.80 $23,889.60
Disclosure

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,608

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
May 15, 2024 Filed May 17, 2024 21:11 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 241 $96.49 $23,254.09
Disclosure

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,860

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
October 20, 2023 Filed Oct 24, 2023 20:23 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 120 $89.05 $10,686.00
Disclosure

SEC source: 0001127602-23-026191 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,101

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
September 12, 2023 Filed Sep 13, 2023 20:19 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 228 $90.65 $20,668.20
Disclosure

SEC source: 0001127602-23-024070 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,221

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:16 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 2,410 $0.00 Strike: $57.60 $0.00
Disclosure

SEC source: 0001127602-23-018423 · form4.xml · derivative · entry 6

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,231

Underlying: Common Stock · 2,410 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:16 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 4,483 $0.00 Strike: $56.57 $0.00
Disclosure

SEC source: 0001127602-23-018423 · form4.xml · derivative · entry 5

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,483

Underlying: Common Stock · 4,483 shares

Expires 2028-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:16 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 2,538 $88.04 $223,445.52
Disclosure

SEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 4

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,449

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report.

F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:16 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 5,053 $88.00 $444,664.00
Disclosure

SEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,987

F2 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:16 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionCommon Stock 2,410 $57.60 $138,816.00
Disclosure

SEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,040

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:16 UTC HAEMONETICS CORP HAE · Entity 3953 Exercise / conversionCommon Stock 4,483 $56.57 $253,603.31
Disclosure

SEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,630

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:31 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 1,087 $83.34 $90,590.58
Disclosure

SEC source: 0001127602-23-016308 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,147

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 16, 2023 Filed May 17, 2023 20:35 UTC HAEMONETICS CORP HAE · Entity 3953 Tax withholdingCommon Stock 250 $89.21 $22,302.50
Disclosure

SEC source: 0001127602-23-015947 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,234

F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:35 UTC HAEMONETICS CORP HAE · Entity 3953 GrantNon-qualified Stock Option (Right to Buy) · Derivative 6,335 $0.00 Strike: $89.16 $0.00
Disclosure

SEC source: 0001127602-23-015947 · form4.xml · derivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,335

Underlying: Common Stock · 6,335 shares

Expires 2030-05-15

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:35 UTC HAEMONETICS CORP HAE · Entity 3953 GrantCommon Stock 2,803 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-015947 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,484

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
October 24, 2022 Filed Oct 26, 2022 20:43 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 75 $80.39 $6,029.25
Disclosure

SEC source: 0001127602-22-024416 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,681

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

Read SEC document
May 19, 2022 Filed May 23, 2022 20:18 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 1,084 $59.10 $64,064.40
Disclosure

SEC source: 0001127602-22-015378 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,756

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
May 16, 2022 Filed May 18, 2022 21:13 UTC HAEMONETICS CORP HAE · Entity 3953 GrantNon-qualified Stock Option (Right to Buy) · Derivative 9,641 $0.00 Strike: $57.60 $0.00
Disclosure

SEC source: 0001127602-22-014995 · form4.xml · derivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,641

Underlying: Common Stock · 9,641 shares

Expires 2029-05-16

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Read SEC document
May 16, 2022 Filed May 18, 2022 21:13 UTC HAEMONETICS CORP HAE · Entity 3953 GrantCommon Stock 4,123 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-22-014995 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,840

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document
October 25, 2021 Filed Oct 27, 2021 20:58 UTC HAEMONETICS CORP HAE · Entity 3953 SaleCommon Stock 75 $71.93 $5,394.75
Disclosure

SEC source: 0001127602-21-027704 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,717

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.